A genome-wide association study [161] of virological response to a PEG-IFN-alpha/Ribavirin (RBV) combination therapy, in 293 Australians with genotype 1 chronic hepatitis C, showed the association of sustained virological response with the expression of the genomic region encoding IL28B (interleukin 28B). Here, IFNL3 is linked to chronic hepatitis C virus infection.